Abstract |
A randomized control trial of TP-5 in rheumatoid arthritis is reported. In a multicentre study, 76 patients were treated with TP-5 50 mg or placebo three times a week for 3 weeks as a slow intravenous injection, and followed for 7 weeks. Clinical parameters such as the Ritchie index and sum score of swollen joints improved significantly on TP-5 compared to placebo. Laboratory parameters did not change but an increased skin test score to common recall antigens was observed. Toxicity was minimal. TP-5 is a potentially useful agent in the treatment of rheumatoid arthritis, although further studies are required to determine the optimal treatment regimen.
|
Authors | B K Kantharia, N J Goulding, N D Hall, J Davies, P J Maddison, P A Bacon, M Farr, J A Wojtulewski, K M Englehart, S P Liyanage |
Journal | British journal of rheumatology
(Br J Rheumatol)
Vol. 28
Issue 2
Pg. 118-23
(Apr 1989)
ISSN: 0263-7103 [Print] England |
PMID | 2650797
(Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial)
|
Chemical References |
- Peptide Fragments
- Thymopoietins
- Thymus Hormones
- Thymopentin
|
Topics |
- Arthritis, Rheumatoid
(blood, drug therapy, physiopathology)
- Clinical Trials as Topic
- Humans
- Hypersensitivity, Delayed
(immunology)
- Peptide Fragments
(adverse effects, therapeutic use)
- Severity of Illness Index
- Skin Tests
- T-Lymphocytes
(classification)
- Thymopentin
- Thymopoietins
(adverse effects, therapeutic use)
- Thymus Hormones
(therapeutic use)
|